Skip to main content

Advertisement

SpringerLink
Log in

Fundoplication is superior to medical therapy for Barrett’s esophagus disease regression and progression: a systematic review and meta-analysis

  • Published:
Surgical Endoscopy Aims and scope Submit manuscript

Abstract

Background

Fundoplication and medical management are current mainstays for management of Barrett’s esophagus (BE), however our understanding of differences in outcomes between these two treatments is limited. The aim of this study was to perform a systematic review and meta-analysis to evaluate the efficacy of these interventions on BE disease regression and progression.

Methods and procedures

A comprehensive search in MEDLINE, EMBASE, Scopus, Web of Science, and Cochrane Library databases was performed on February 22, 2021. Inclusion criteria were studies with both medical and surgical management comparators, BE diagnosis prior to treatment, patients aged ≥ 18 years, and studies with greater than five patients. Primary outcomes of interest included evaluating changes in histopathologic BE regression and disease progression between interventions. Meta-analysis was performed using a Mantel–Haenszel random-effects model (RevMan 5.4.1).

Results

A total of 7231 studies were retrieved after initial search with nine studies (1 randomized trial, 7 prospective cohorts, 1 retrospective cohort) meeting final inclusion criteria. Of included studies, 890 (65%) patients received medical management while 470 (35%) received surgical management. Medical management included proton pump inhibitors (n = 807, 91%; 6 studies), H2-receptor blockers (n = 40, 4% patients; 3 studies), and combination therapy (n = 43, 5%; 1 study). Nissen fundoplication was the most commonly performed type of fundoplication (n = 265, 93%). Median length of follow-up ranged from 1.5–7 years. Meta-analysis revealed that fundoplication was associated with improved histopathologic regression of metaplasia/low-grade dysplasia (OR 4.38; 95% CI 2.28–8.42; p < 0.00001) and disease progression to dysplasia/adenocarcinoma (OR 0.34; 95% CI 0.12–0.96; p = 0.04) compared to medical therapy.

Conclusion

Fundoplication is superior to medical therapy with regards to improved odds of histopathologic BE disease regression and disease progression. Additional randomized trials which directly compare medical management and surgical intervention are required to delineate the optimal delivery and timing of these interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P (2011) Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 365:1375–1383. https://doi.org/10.1056/NEJMoa1103042

    Article  CAS  PubMed  Google Scholar 

  2. Marques de Sá I, Pereira AD, Sharma P, Dinis-Ribeiro M (2020) Systematic review of the published guidelines on Barrett’s esophagus: should we stress the consensus or the differences? Dis esophagus Off J Int Soc Dis Esophagus. https://doi.org/10.1093/dote/doaa115

    Article  Google Scholar 

  3. Kestens C, Offerhaus GJA, van Baal JWPM, Siersema PD (2016) Patients with Barrett’s esophagus and persistent low-grade dysplasia have an increased risk for high-grade dysplasia and cancer. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 14:956-962.e1. https://doi.org/10.1016/j.cgh.2015.12.027

    Article  Google Scholar 

  4. Canadian Cancer Society (2019) Survival Statistics for Esophageal Cancer. Available at https://www.cancer.ca/en/cancer-information/cancer-type/esophageal/prognosis-and-survival/survival-statistics/?region=qc. Accessed 16 Jan 2020

  5. Runge TM, Abrams JA, Shaheen NJ (2015) Epidemiology of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 44:203–231. https://doi.org/10.1016/j.gtc.2015.02.001

    Article  PubMed  PubMed Central  Google Scholar 

  6. Maret-Ouda J, Markar SR, Lagergren J (2020) Gastroesophageal reflux disease: a review. JAMA 324:2536–2547. https://doi.org/10.1001/jama.2020.21360

    Article  CAS  PubMed  Google Scholar 

  7. Society of American Gastrointestinal and Endoscopic Surgeons (2020) Survival Statistics for Esophageal Cancer. https://www.sages.org/publications/guidelines/guidelines-for-surgical-treatment-of-gastroesophageal-reflux-disease-gerd/. Accessed 3 Dec 2020

  8. Attwood SEA, Lundell L, Ell C, Galmiche J-P, Hatlebakk J, Fiocca R, Lind T, Eklund S, Junghard O (2008) Standardization of surgical technique in antireflux surgery: the LOTUS trial experience. World J Surg 32:995–998. https://doi.org/10.1007/s00268-007-9409-4

    Article  PubMed  Google Scholar 

  9. Maret-Ouda J, Konings P, Lagergren J, Brusselaers N (2016) Antireflux surgery and risk of esophageal adenocarcinoma: a systematic review and meta-analysis. Ann Surg 263:251–257. https://doi.org/10.1097/SLA.0000000000001438

    Article  PubMed  Google Scholar 

  10. Haddaway NR, Collins AM, Coughlin DKS (2015) The role of google scholar in evidence reviews and its applicability to grey literature searching. PLoS ONE. https://doi.org/10.1371/journal.pone.0138237

    Article  PubMed  PubMed Central  Google Scholar 

  11. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2020) Cochrane handbook for systematic reviews of interventions version 6.1. Available at www.training.cochrane.org/handbook. Accessed 15 Dec 2020

  12. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557

    Article  PubMed  PubMed Central  Google Scholar 

  13. Attwood SE, Barlow AP, Norris TL, Watson A (1992) Barrett’s oesophagus: effect of antireflux surgery on symptom control and development of complications. Br J Surg 79:1050–1053. https://doi.org/10.1002/bjs.1800791021

    Article  CAS  PubMed  Google Scholar 

  14. Gurski RR, Peters JH, Hagen JA, DeMeester SR, Bremner CG, Chandrasoma PT, DeMeester TR (2003) Barrett’s esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg 196:703–706. https://doi.org/10.1016/S1072-7515(03)00147-9

    Article  Google Scholar 

  15. Markar SR, Arhi C, Leusink A, Vidal-Diez A, Karthikesalingam A, Darzi A, Lagergren J, Hanna GB (2018) The influence of antireflux surgery on esophageal cancer risk in England: national population-based cohort study. Ann Surg 268:861–867. https://doi.org/10.1097/SLA.0000000000002890

    Article  PubMed  Google Scholar 

  16. Oberg S, Wenner J, Johansson J, Walther B, Willén R (2005) Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 242:49–54. https://doi.org/10.1097/01.sla.0000167864.46462.9f

    Article  PubMed  PubMed Central  Google Scholar 

  17. Parrilla P, Martínez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J, Canteras M (2003) Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg 237:291–298. https://doi.org/10.1097/01.SLA.0000055269.77838.8E

    Article  PubMed  PubMed Central  Google Scholar 

  18. Rossi M, Barreca M, de Bortoli N, Renzi C, Santi S, Gennai A, Bellini M, Costa F, Conio M, Marchi S (2006) Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study. Ann Surg 243:58–63. https://doi.org/10.1097/01.sla.0000194085.56699.db

    Article  PubMed  PubMed Central  Google Scholar 

  19. Trentino MDP, Trifero MDM, Marzullo MDA, Arcese MDR, Correnti MDFS, Pappalardo MDG, Castrini MDG (1990) Biomarkers’ evaluation for early neoplastic degeneration in Barrett’s esophagus. A preliminary report on 12 cases. Dis Esophagus 3:29–36. https://doi.org/10.1093/dote/3.1.29

    Article  Google Scholar 

  20. Tolone S, Limongelli P, Romano M, Federico A, Docimo G, Ruggiero R, Brusciano L, Del Genio G, Docimo L (2015) The patterns of reflux can affect regression of non-dysplastic and low-grade dysplastic Barrett’s esophagus after medical and surgical treatment: a prospective case-control study. Surg Endosc 29:648–657. https://doi.org/10.1007/s00464-014-3713-5

    Article  PubMed  Google Scholar 

  21. Zaninotto G, Parente P, Salvador R, Farinati F, Tieppo C, Passuello N, Zanatta L, Fassan M, Cavallin F, Costantini M, Mescoli C, Battaglia G, Ruol A, Ancona E, Rugge M (2012) Long-term follow-up of Barrett’s epithelium: medical versus antireflux surgical therapy. J Gastrointest Surg Off J Soc Surg Aliment Tract 16:5–7. https://doi.org/10.1007/s11605-011-1739-8

    Article  Google Scholar 

  22. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ, Association AG (2011) American gastroenterological association technical review on the management of Barrett’s esophagus. Gastroenterol 140:e18–e13. https://doi.org/10.1053/j.gastro.2011.01.031

    Article  Google Scholar 

  23. Oh DS, Demeester SR (2010) Pathophysiology and treatment of Barrett’s esophagus. World J Gastroenterol 16:3762–3772. https://doi.org/10.3748/wjg.v16.i30.3762

    Article  PubMed  PubMed Central  Google Scholar 

  24. Tobey NA, Hosseini SS, Argote CM, Dobrucali AM, Awayda MS, Orlando RC (2004) Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol 99:13–22. https://doi.org/10.1046/j.1572-0241.2003.04018.x

    Article  CAS  PubMed  Google Scholar 

  25. Oberg S, Peters JH, DeMeester TR, Chandrasoma P, Hagen JA, Ireland AP, Ritter MP, Mason RJ, Crookes P, Bremner CG (1997) Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg 226:522–532. https://doi.org/10.1097/00000658-199710000-00013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Nasr AO, Dillon MF, Conlon S, Downey P, Chen G, Ireland A, Leen E, Bouchier-Hayes D, Walsh TN (2012) Acid suppression increases rates of Barrett’s esophagus and esophageal injury in the presence of duodenal reflux. Surgery 151:382–390. https://doi.org/10.1016/j.surg.2011.08.021

    Article  PubMed  Google Scholar 

  27. Jürgens S, Meyer F, Spechler SJ, Souza R (2012) The role of bile acids in the neoplastic progression of Barrett’s esophagus - a short representative overview. Z Gastroenterol 50:1028–1034. https://doi.org/10.1055/s-0032-1312922

    Article  CAS  PubMed  Google Scholar 

  28. Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA (1995) Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 222:525–533. https://doi.org/10.1097/00000658-199522240-00010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Stein HJ, Kauer WKH, Feussner H, Siewert JR (1998) Bile reflux in benign and malignant Barrett’s esophagus: effect of medical acid suppression and Nissen fundoplication. J Gastrointest Surg 2:333–341. https://doi.org/10.1016/S1091-255X(98)80072-3

    Article  CAS  PubMed  Google Scholar 

  30. Niebisch S, Fleming FJ, Galey KM, Wilshire CL, Jones CE, Litle VR, Watson TJ, Peters JH (2012) Perioperative risk of laparoscopic fundoplication: safer than previously reported—analysis of the American college of surgeons national surgical quality improvement program 2005 to 2009. JACS 215:61–68. https://doi.org/10.1016/j.jamcollsurg.2012.03.022

    Article  Google Scholar 

  31. Cameron AJ (1999) Barrett’s esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 94:2054–2059. https://doi.org/10.1111/j.1572-0241.1999.01277.x

    Article  CAS  PubMed  Google Scholar 

  32. Roman S, Kahrilas PJ (2015) Mechanisms of Barrett’s oesophagus (clinical): LOS dysfunction, hiatal hernia, peristaltic defects. Best Pract Res Clin Gastroenterol 29:17–28. https://doi.org/10.1016/j.bpg.2014.11.002

    Article  PubMed  Google Scholar 

  33. Van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MCJM, Kuipers EJ (2006) Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 24:377–385. https://doi.org/10.1111/j.1365-2036.2006.02982.x

    Article  CAS  PubMed  Google Scholar 

  34. Hungin APS, Hill C, Molloy-Bland M, Raghunath A (2012) Systematic review: patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 10:109–116. https://doi.org/10.1016/j.cgh.2011.07.008

    Article  Google Scholar 

  35. El-Serag HB, Fitzgerald S, Richardson P (2009) The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol 104:2161–2167. https://doi.org/10.1038/ajg.2009.312

    Article  PubMed  Google Scholar 

  36. Corey KE, Schmitz SM, Shaheen NJ (2003) Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett’s esophagus? A meta-analysis. Am J Gastroenterol 98:2390–2394. https://doi.org/10.1111/j.1572-0241.2003.08702.x

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada

    H. Wilson

  2. Department of Surgery, University of Alberta, Edmonton, AB, Canada

    V. Mocanu, W. Sun, J. Dang, U. Jogiat, N. Switzer & S. Karmali

  3. John W. Scott Health Sciences Library, University of Alberta, Edmonton, AB, Canada

    J. Kung

  4. Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada

    C. Wong

Authors
  1. H. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Mocanu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Dang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U. Jogiat
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Kung
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. Switzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Karmali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Mocanu.

Ethics declarations

Disclosures

Ms. Wilson and Kung, and Drs. Mocanu, Sun, Deng, Jogiat, Switzer, Wong and Karmali have no conflicts of interest or financial ties to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wilson, H., Mocanu, V., Sun, W. et al. Fundoplication is superior to medical therapy for Barrett’s esophagus disease regression and progression: a systematic review and meta-analysis. Surg Endosc 36, 2554–2563 (2022). https://doi.org/10.1007/s00464-021-08543-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00464-021-08543-6

Keywords

Search

Navigation